TRAWS PHARMA INC (TRAW)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.55+1.49%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TRAW
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -89.7% |
| Our one-year growth estimate | diamond | 100.0% |
Growth built into the price is above our model estimate.
The price assumes 189.7 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
TRAW — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued
Dated 2026-07-31
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 29, 2026, Traws Pharma, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock was below $1.00 per share for at least 30 consecutive business days, the Company is not currently in compliance with the minimum bi…
Why it matters: Earnings results will show Traws' financial health and progress. This may change investor feelings.
Watch forEarnings show better financial metrics than in Q1 2026.
Also watch forEarnings reveal further losses or no revenue growth compared to Q1 2026.
Why it matters: Starting this trial is a key step in proving TXM's potential as a flu prophylactic. Success could boost investor confidence.
Supportive ifTraws announces the start of the human challenge trial for TXM as planned.
Worry ifTraws delays the start of the human challenge trial beyond Q2 2026.
Why it matters: Creating a hantavirus treatment could help Traws lead in fighting this deadly disease.
Supportive ifTraws plans to share progress on a hantavirus treatment candidate by Q4 2026.
Worry ifThere are no updates or progress on hantavirus treatment by Q4 2026.
Why it matters: Good data could show that tivoxavir marboxil works well and is safe. This could help investor confidence and stock performance.
Supportive ifTraws shares good topline data from the Phase 2a Challenge trial for tivoxavir.
Worry ifData from the trial shows disappointing results or safety concerns.
Why it matters: This study must finish to confirm TXM's dose and effectiveness before the Challenge Trial.
Supportive ifThe Phase 1 Bridging Study for TXM is completed and shows positive results.
Worry ifThe Phase 1 Bridging Study is delayed or shows negative results.
Why it matters: Good use of money can make a company stronger. Investors want to see funds used well.
Supportive ifThey announced raising over $10M from the private placement.
Worry ifNo updates or delays in the private placement process.
Why it matters: Approval is crucial for Traws to start the human challenge trial for TXM. This trial is key for proving TXM's effectiveness as a flu treatment.
Supportive ifMHRA grants approval for the Phase 2a human influenza Challenge study by the end of Q3 2026.
Worry ifMHRA denies approval or delays it beyond Q3 2026.
Why it matters: Updates on cash position will indicate if Traws can fund operations beyond Q1 2027. This is crucial for ongoing clinical trials.
Watch forTraws has over $5 million in cash and equivalents, showing strong finances.
Also watch forTraws has less than $5 million in cash, raising worries about future funding.
Why it matters: TRAW needs better financial performance. This will help them regain investor trust.
Supportive ifNet income turns positive for the next quarter.
Worry ifNet income remains negative or worsens in the next quarter.
Why it matters: Updates will show how effectively Traws Pharma is using funds from the recent private placement. This affects future growth.
Supportive ifManagement will share news about a new investment or partnership. This will be paid for by the private placement.
Worry ifNo updates or negative news regarding the use of funds from the private placement.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$377 on $10,000 · ±3.8% | How much price usually moves either way. |
| Bad day | $1,096 loss on $10,000 · 11.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,591 loss on $10,000 · 85.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.